NCT01403948View on ClinicalTrials.gov

BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 1, 2011

Primary Completion Date

November 14, 2017

Study Completion Date

February 28, 2018

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

BI 836826

Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion

Trial Locations (12)

12200

Charité - Universitätsmedizin Berlin, Berlin

13273

INS Paoli-Calmettes, Marseille

20099

Asklepios Klinik St. Georg, Hamburg

37075

Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen

60590

Universitätsklinikum Frankfurt, Frankfurt am Main

69120

Universitätsklinikum Heidelberg, Heidelberg

69495

HOP Lyon Sud, Pierre-Bénite

89081

Universitätsklinikum Ulm, Ulm

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

07740

Universitätsklinikum Jena, Jena

110-744

Seoul National University Hospital, Seoul

135-710

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01403948 - BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) | Biotech Hunter | Biotech Hunter